Literature DB >> 21235405

The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset.

Leslie J Findley1, Eifiona Wood, Julia Lowin, Claudia Roeder, Annika Bergman, Mathias Schifflers.   

Abstract

BACKGROUND: To evaluate the cost burden of patients with advanced Parkinson's disease (PD) according to the waking hours per day spent in OFF state. An analysis of resource use comprising medical services, professional care and informal care data from an observational, cross-sectional study was conducted.
METHODS: A total of 60 physicians comprising 40 neurologists and 20 geriatricians across the UK participating in the Adelphi PD Disease Specific Programme took part. There were 302 PD patients at H&amp;Y stages 3-5. Patients were characterised according to the percentage of time per day spent in OFF state (<25%, 26-50%, 51-75%, >75%).
RESULTS: Average 12-monthly total costs increased according to the time spent in OFF state from £25,630 in patients spending less than 25% of their waking hours in OFF to £62,147 for patients spending more than 75% of their time in OFF. Overall, 7% of costs were attributed to direct medical care, while 93% were split between direct non-medical professional care (50%) and indirect informal care (43%). LIMITATIONS: Low patient numbers in the more advanced disease stages of PD led to very little or no data to directly inform some of the severe health states of the analysis. Data gaps were filled in with data derived from a regression analysis which may affect the robustness of the analysis.
CONCLUSION: This study illustrates the increasing costs of advancing PD, in particular related to the time spent in OFF state, and identifies that the foremost cost burden is associated with the care needs of the patient rather than medical services.

Entities:  

Mesh:

Year:  2011        PMID: 21235405     DOI: 10.3111/13696998.2010.551164

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  19 in total

1.  Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.

Authors:  Luca Degli Esposti; Carlo Piccinni; Diego Sangiorgi; Flavio Nobili; Stefano Buda
Journal:  Neurol Sci       Date:  2015-10-16       Impact factor: 3.307

2.  Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation.

Authors:  Jing Han Ng; Angela An Qi See; Zheyu Xu; Nicolas Kon Kam King
Journal:  J Neurol       Date:  2020-05-04       Impact factor: 4.849

Review 3.  Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review.

Authors:  Nafsika Afentou; Johan Jarl; Ulf-G Gerdtham; Sanjib Saha
Journal:  Mov Disord Clin Pract       Date:  2019-04-11

Review 4.  Comparison of informal care time and costs in different age-related dementias: a review.

Authors:  Nadège Costa; Laura Ferlicoq; Hélène Derumeaux-Burel; Thomas Rapp; Valérie Garnault; Sophie Gillette-Guyonnet; Sandrine Andrieu; Bruno Vellas; Michel Lamure; Alain Grand; Laurent Molinier
Journal:  Biomed Res Int       Date:  2012-12-05       Impact factor: 3.411

5.  Economic Burden Analysis of Parkinson's Disease Patients in China.

Authors:  Jun-Xiu Yang; Lei Chen
Journal:  Parkinsons Dis       Date:  2017-06-14

6.  Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study.

Authors:  Monika Balzer-Geldsetzer; Joaquim Ferreira; Per Odin; Bastiaan R Bloem; Wassilios G Meissner; Stefan Lorenzl; Michael Wittenberg; Richard Dodel; Anette Schrag
Journal:  BMC Neurol       Date:  2018-11-05       Impact factor: 2.474

7.  Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.

Authors:  Katarzyna Smilowska; Daniel J van Wamelen; Tomasz Pietrzykowski; Alexander Calvano; Carmen Rodriguez-Blazquez; Pablo Martinez-Martin; Per Odin; K Ray Chaudhuri
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

8.  Impact of Friedreich's Ataxia on health-care resource utilization in the United Kingdom and Germany.

Authors:  Paola Giunti; Julia Greenfield; Alison J Stevenson; Michael H Parkinson; Jodie L Hartmann; Ruediger Sandtmann; James Piercy; Jamie O'Hara; Leo Ruiz Casas; Fiona M Smith
Journal:  Orphanet J Rare Dis       Date:  2013-02-28       Impact factor: 4.123

9.  Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary.

Authors:  Gertrúd Tamás; László Gulácsi; Dániel Bereczki; Petra Baji; Annamária Takáts; Valentin Brodszky; Márta Péntek
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

Review 10.  Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders.

Authors:  Laura Kay; Ilse S Pienaar; Ruwini Cooray; Gary Black; Meera Soundararajan
Journal:  Mol Neurobiol       Date:  2018-02-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.